Erythema multiforme-like reaction following COVID-19 vaccination
- PMID: 35962494
- DOI: 10.25259/IJDVL_791_2021
Erythema multiforme-like reaction following COVID-19 vaccination
Comment on
-
Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: A retrospective study.J Am Acad Dermatol. 2020 Mar;82(3):606-611. doi: 10.1016/j.jaad.2019.09.036. Epub 2019 Sep 25. J Am Acad Dermatol. 2020. PMID: 31562941
-
A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.Clin Exp Dermatol. 2021 Oct;46(7):1325-1327. doi: 10.1111/ced.14714. Epub 2021 May 25. Clin Exp Dermatol. 2021. PMID: 33914926 Free PMC article. No abstract available.
References
-
- Belhekar MN, Taur SR, Munshi RP,. A study of agreement between the Naranjo algorithm and WHO-UMC criteria for causality assessment of adverse drug reactions. Indian J Pharmacol. 2014; 46:117-20
-
- Hartwig SC, Siegel J, Schneider PJ,. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992; 49:2229-32
-
- Kounis NG, Koniari I, de Gregorio C, Velissaris D, Petalas K, Brinia A, et al. Allergic reactions to current available COVID-19 vaccinations: Pathophysiology, causality, and therapeutic considerations. Vaccines (Basel). 2021; 9:221
-
- Lavery MJ, Nawimana S, Parslew R, Stewart L,. A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. Clin Exp Dermatol. 2021; 46:1325-7
-
- Stone CA Jr, Rukasin CRF, Beachkofsky TM, Phillips EJ,. Immune-mediated adverse reactions to vaccines. Br J Clin Pharmacol. 2019; 85:2694-706
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
